En undersøgelse til evaluering af TAR-210 versus enkeltagent intravesikal kræftbehandling hos deltagere med blærekræft (MoonRISe-1)
En fase 3, randomiseret undersøgelse, der evaluerer effektiviteten og sikkerheden af TAR-210 Erdafitinib intravesikalt indgivelsessystem versus enkeltmiddel intravesikal kemoterapi hos deltagere med ikke-muskelinvasiv blærekræft (IR-NMIBC) og følsomme FGFR-ændringer
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Study Contact
- Telefonnummer: 844-434-4210
- E-mail: Participate-In-This-Study1@its.jnj.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1419AHN
- Aktiv, ikke rekrutterende
- Hospital Sirio Libanes
-
Chabas, Argentina, C1425
- Aktiv, ikke rekrutterende
- Investigaciones Clinico Moleculares (ICM)
-
Córdoba, Argentina, 5000
- Aktiv, ikke rekrutterende
- Cemaic Centro Privado de Especialidades Medicas Ambulatorias e Investigacion Clinica
-
Córdoba, Argentina, X5000KPH
- Aktiv, ikke rekrutterende
- Centro Urologico Profesor Bengio
-
Mar del Plata, Argentina, B7602
- Aktiv, ikke rekrutterende
- Hospital Privado de la Comunidad
-
Rosario, Argentina, 2000
- Aktiv, ikke rekrutterende
- Sanatorio de la Mujer
-
-
-
-
-
Aalst, Belgien, 9300
- Rekruttering
- AZORG campus Aalst Moorselbaan
-
Brugge (Bruges), Belgien, 8000
- Rekruttering
- AZ Sint-Jan
-
Edegem, Belgien, 2650
- Afsluttet
- UZ Antwerpen
-
Gent (Ghent), Belgien, 9000
- Rekruttering
- AZ Maria Middelares
-
Leuven, Belgien, 3000
- Aktiv, ikke rekrutterende
- Universitair Ziekenhuis Gasthuisberg
-
Sint-Niklaas, Belgien, 9100
- Rekruttering
- Vitaz
-
Yvoir, Belgien, 5530
- Rekruttering
- CHU UCL Namur - Site Godinne
-
-
-
-
-
Barretos, Brasilien, 14780-070
- Aktiv, ikke rekrutterende
- Fundacao Pio XII
-
Campinas, Brasilien, 13083-888
- Afsluttet
- Universidade Estadual De Campinas
-
Natal, Brasilien, 59062 000
- Aktiv, ikke rekrutterende
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasilien, 90035-001
- Aktiv, ikke rekrutterende
- Hospital Moinhos de Vento
-
Porto Alegre, Brasilien, 90050 170
- Aktiv, ikke rekrutterende
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Salvador, Brasilien, 41810-011
- Aktiv, ikke rekrutterende
- HBA SA Assitencia Medica e Hospitalar
-
Santo André, Brasilien, 09060-650
- Aktiv, ikke rekrutterende
- CEPHO Centro de Estudos e Pesquisa de Hematologia e Oncologia
-
São Paulo, Brasilien, 01246-000
- Aktiv, ikke rekrutterende
- Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
-
São Paulo, Brasilien, 01509 900
- Afsluttet
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasilien, 01221-020
- Aktiv, ikke rekrutterende
- Irmandade Santa Casa de Misericordia de Sao Paulo
-
São Paulo, Brasilien, 01323 900
- Aktiv, ikke rekrutterende
- Real e Benemérita Associação Portuguesa de Beneficência
-
-
-
-
-
Aarhus, Danmark, 8200
- Rekruttering
- Aarhus University Hospital
-
Copenhagen, Danmark, 2100
- Rekruttering
- Rigshospitalet
-
Herlev, Danmark, 2730
- Rekruttering
- Herlev Hospital
-
Odense, Danmark, 5000
- Rekruttering
- Odense Universitetshospital
-
Roskilde, Danmark, 4000
- Rekruttering
- Zealand University Hospital
-
-
-
-
-
Bristol, Det Forenede Kongerige, BS105NB
- Aktiv, ikke rekrutterende
- Southmead Hospital
-
London, Det Forenede Kongerige, W6 8RF
- Aktiv, ikke rekrutterende
- Charing Cross Hospital
-
London, Det Forenede Kongerige, EC1A 7BE
- Aktiv, ikke rekrutterende
- St Bartholomews Hospital
-
Newcastle upon Tyne, Det Forenede Kongerige, NE7 7DN
- Aktiv, ikke rekrutterende
- Newcastle Freeman Hospital
-
Sheffield, Det Forenede Kongerige, S10 2SJ
- Aktiv, ikke rekrutterende
- Sheffield Teaching Hospitals NHS Foundation Trust
-
Southampton, Det Forenede Kongerige, SO16 6YD
- Aktiv, ikke rekrutterende
- Southampton General Hospital
-
Sutton, Det Forenede Kongerige, SM2 5PT
- Aktiv, ikke rekrutterende
- Royal Marsden Hospital
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72211
- Afsluttet
- Arkansas Urology
-
-
California
-
Los Alamitos, California, Forenede Stater, 90720
- Aktiv, ikke rekrutterende
- Genesis Research LLC
-
Los Angeles, California, Forenede Stater, 90033
- Aktiv, ikke rekrutterende
- USC Norris Comprehensive Cancer Center
-
Orange, California, Forenede Stater, 92868
- Aktiv, ikke rekrutterende
- University of California Irvine Medical Center
-
San Diego, California, Forenede Stater, 92123
- Aktiv, ikke rekrutterende
- Om Research LLC
-
Sherman Oaks, California, Forenede Stater, 91411
- Afsluttet
- Genesis Research LLC 1
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Afsluttet
- University of Colorado Cancer Center Anschultz Cancer Pavilion
-
Lakewood, Colorado, Forenede Stater, 80228
- Aktiv, ikke rekrutterende
- Colorado Clinical Research
-
San Luis, Colorado, Forenede Stater, 63141
- Afsluttet
- Mercy Research
-
San Luis, Colorado, Forenede Stater, 63141
- Aktiv, ikke rekrutterende
- Specialty Clinical Research of St Louis
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- Aktiv, ikke rekrutterende
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Afsluttet
- Northwestern University
-
-
Indiana
-
Jeffersonville, Indiana, Forenede Stater, 47130
- Afsluttet
- First Urology
-
-
Kansas
-
Wichita, Kansas, Forenede Stater, 67226
- Aktiv, ikke rekrutterende
- Wichita Urology Group
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70121-2429
- Aktiv, ikke rekrutterende
- Ochsner Health System
-
-
Maryland
-
Hanover, Maryland, Forenede Stater, 21076
- Afsluttet
- Chesapeake Urology Research Associates
-
-
Massachusetts
-
Boston, Massachusetts, Forenede Stater, 02115
- Afsluttet
- Brigham And Women's Hospital
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48201
- Aktiv, ikke rekrutterende
- Karmanos Cancer Institute
-
Royal Oak, Michigan, Forenede Stater, 48073
- Aktiv, ikke rekrutterende
- Comprehensive Urology
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Aktiv, ikke rekrutterende
- The Urology Center, PC
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Aktiv, ikke rekrutterende
- Cancer Institute Of New Jersey
-
-
New York
-
New York, New York, Forenede Stater, 10065
- Aktiv, ikke rekrutterende
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Forenede Stater, 10016
- Afsluttet
- Integrated Medical Professionals
-
Syracuse, New York, Forenede Stater, 13210
- Aktiv, ikke rekrutterende
- SUNY Upstate Med Univ
-
Syracuse, New York, Forenede Stater, 13210
- Aktiv, ikke rekrutterende
- Associated Medical Professionals of Ny
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Aktiv, ikke rekrutterende
- Levine Cancer Institute
-
Raleigh, North Carolina, Forenede Stater, 27612
- Aktiv, ikke rekrutterende
- Associated Urologists of North Carolina
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Forenede Stater, 19004
- Afsluttet
- MidLantic Urology
-
Lancaster, Pennsylvania, Forenede Stater, 17604
- Aktiv, ikke rekrutterende
- Keystone Urology Specialists
-
-
South Carolina
-
Myrtle Beach, South Carolina, Forenede Stater, 29572
- Aktiv, ikke rekrutterende
- Carolina Urologic Research Center
-
-
Tennessee
-
Germantown, Tennessee, Forenede Stater, 38138
- Aktiv, ikke rekrutterende
- The Conrad Pearson Clinic
-
Knoxville, Tennessee, Forenede Stater, 37920
- Afsluttet
- University of Tennessee Medical Center
-
Nashville, Tennessee, Forenede Stater, 37209
- Aktiv, ikke rekrutterende
- Urology Associates
-
-
Texas
-
Austin, Texas, Forenede Stater, 78745
- Aktiv, ikke rekrutterende
- Urology Austin
-
Dallas, Texas, Forenede Stater, 75231
- Aktiv, ikke rekrutterende
- Urology Clinics of North Texas
-
Dallas, Texas, Forenede Stater, 75390
- Afsluttet
- UT Southwestern
-
Houston, Texas, Forenede Stater, 77027
- Aktiv, ikke rekrutterende
- Houston Metro Urology
-
-
Washington
-
Spokane, Washington, Forenede Stater, 99202
- Aktiv, ikke rekrutterende
- Spokane Urology
-
-
-
-
-
Lille, Frankrig, 59000
- Afsluttet
- Hospital Center University De Lille
-
Limoges, Frankrig, 87000
- Rekruttering
- Polyclinique de Limoges - Francois Chenieux
-
Lyon, Frankrig, 69003
- Rekruttering
- Hôpital Edouard Herriot
-
Marseille, Frankrig, 13009
- Rekruttering
- Institut Paoli Calmettes
-
Paris, Frankrig, 75010
- Rekruttering
- Hopital Saint Louis
-
Paris, Frankrig, 75013
- Rekruttering
- CHU Pitie Salpetriere
-
Paris, Frankrig, 75018
- Rekruttering
- APHP - Hopital Bichat - Claude Bernard
-
Quint-Fonsegrives, Frankrig, 31130
- Rekruttering
- Clinique de la Croix du Sud
-
Rennes, Frankrig, 35000
- Afsluttet
- Chu Rennes Hopital Pontchaillou
-
Toulouse, Frankrig, 31059
- Rekruttering
- CHU Rangueil
-
Villejuif, Frankrig, 94805
- Rekruttering
- Institut Gustave Roussy
-
-
-
-
-
Hong Kong, Hong Kong
- Aktiv, ikke rekrutterende
- Queen Mary Hospital
-
Hong Kong, Hong Kong
- Aktiv, ikke rekrutterende
- Prince Of Wales Hospital
-
-
-
-
-
Cork, Irland, T12 DC4A
- Aktiv, ikke rekrutterende
- Cork University Hospital
-
Dublin, Irland, D07 A8NN
- Aktiv, ikke rekrutterende
- Mater Misericordiae University Hospital
-
Dublin, Irland, D07 WKW8
- Aktiv, ikke rekrutterende
- Mater Private Hospital
-
Dublin, Irland, D24 NR0A
- Aktiv, ikke rekrutterende
- Adelaide and Meath Hospital
-
-
-
-
-
Haifa, Israel, 3109601
- Rekruttering
- Rambam Health Care Campus
-
Ramat Gan, Israel, 52621
- Rekruttering
- Sheba Medical Center
-
Sderot, Israel, 13100
- Rekruttering
- Ziv Medical Center
-
Tel Aviv, Israel, 6423906
- Rekruttering
- Sourasky Medical Center
-
Yeruham, Israel, 9112001
- Afsluttet
- Hadassah University Hospita Ein Kerem
-
-
-
-
-
Arezzo, Italien, 52100
- Rekruttering
- Ospedale S. Donato Arezzo, USL 8 - U.O. Oncologia Medica
-
Bergamo, Italien, 24125
- Rekruttering
- Cliniche Humanitas Gavazzeni
-
Brescia, Italien, 25123
- Rekruttering
- ASST Spedali Civili Brescia
-
Milan, Italien, 20133
- Rekruttering
- Istituto Dei Tumori Di Milano
-
Milan, Italien, 20132
- Afsluttet
- Ospedale San Raffaele
-
Romagnano, Italien, 00128
- Rekruttering
- Universita Campus Bio-Medico di Roma
-
Romagnano, Italien, 00144
- Rekruttering
- Istituto Nazionale Tumori Regina Elena
-
Rozzano, Italien, 20089
- Rekruttering
- Istituto Clinico Humanitas
-
Torino, Italien, 10126
- Rekruttering
- A.O.Citta della Salute e della Scienza di Torino
-
-
-
-
-
Amagasaki, Japan, 660 8550
- Aktiv, ikke rekrutterende
- Hyogo Prefectural Amagasaki General Medical Center
-
Kawasaki, Japan, 216 8511
- Rekruttering
- St Marianna University Hospital
-
Kobe, Japan, 650 0047
- Aktiv, ikke rekrutterende
- Kobe City Medical Center General Hospital
-
Kumamoto, Japan, 860 0008
- Aktiv, ikke rekrutterende
- National Hospital Organization Kumamoto Medical Center
-
Osaka, Japan, 541 8567
- Rekruttering
- Osaka International Cancer Institute
-
Saitama, Japan, 350 8550
- Aktiv, ikke rekrutterende
- Saitama Medical Center
-
Wakayama, Japan, 640 8558
- Aktiv, ikke rekrutterende
- JRC Wakayama Medical Center
-
Yokohama, Japan, 221 0855
- Rekruttering
- Yokohama Municipal Citizen's Hospital
-
Yokohama, Japan, 232 0024
- Aktiv, ikke rekrutterende
- Yokohama City University Medical Center
-
Yokosuka, Japan, 238 8558
- Rekruttering
- Yokosuka Kyosai Hospital
-
Ōta-ku, Japan
- Rekruttering
- Gunma Prefectural Cancer Center
-
-
-
-
-
Beijing, Kina, 100191
- Aktiv, ikke rekrutterende
- Peking University Third Hospital
-
Beijing, Kina, 100050
- Aktiv, ikke rekrutterende
- Beijing Friendship Hospital Capital Medical University
-
Changsha, Kina, 410013
- Aktiv, ikke rekrutterende
- Hunan Cancer hospital
-
Chengdu, Kina, 610041
- Aktiv, ikke rekrutterende
- West China School of Medicine/West China Hospital, Sichuan University
-
Chengdu, Kina, 610014
- Aktiv, ikke rekrutterende
- The Third People's Hospital of Chengdu
-
Chongqing, Kina, 400033
- Aktiv, ikke rekrutterende
- Chongqing Cancer Hospital
-
Fuzhou, Kina, 350001
- Aktiv, ikke rekrutterende
- Fujian Medical University Union Hospital
-
Guangzhou, Kina, 510060
- Aktiv, ikke rekrutterende
- Sun Yat Sen University Cancer Center
-
Nanjing, Kina, 210008
- Aktiv, ikke rekrutterende
- Nanjing Drum Tower Hospital
-
Nanjing, Kina, 210009
- Aktiv, ikke rekrutterende
- Zhongda Hospital Southeast University
-
Shanghai, Kina, 200031
- Aktiv, ikke rekrutterende
- Huadong Hospital Affiliated to Fudan University
-
Tianjin, Kina, 300061
- Aktiv, ikke rekrutterende
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Kina, 325000
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Kina, 430032
- Aktiv, ikke rekrutterende
- Tongji Hospital Tongji Medical College of Huazhong University of Science and Technology
-
Xinshi, Kina, 710063
- Aktiv, ikke rekrutterende
- The First Affiliated Hospital of Xian Jiaotong University
-
Xuzhou, Kina, 221004
- Aktiv, ikke rekrutterende
- The Affiliated Hospital of Xuzhou Medical University
-
Ürümqi, Kina, 830011
- Aktiv, ikke rekrutterende
- Cancer Hospital of Xinjiang Medical University
-
-
-
-
-
Bialystok, Polen, 15 276
- Aktiv, ikke rekrutterende
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polen, 85 048
- Aktiv, ikke rekrutterende
- IN VIVO Sp. z o.o
-
Bydgoszcz, Polen, 85 796
- Afsluttet
- Centrum Onkologii im Prof F Lukaszczyka w Bydgoszczy
-
Lublin, Polen, 20 090
- Aktiv, ikke rekrutterende
- Uniwersytecki Szpital Kliniczny nr 4
-
Przemyśl, Polen, 37 700
- Aktiv, ikke rekrutterende
- Wojewodzki Szpital im Sw Ojca Pio w Przemyslu
-
Tarnów, Polen, 33-100
- Aktiv, ikke rekrutterende
- Szpital Wojewodzki Im Sw Lukasza Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Tarnowie
-
Torun, Polen, 87-100
- Afsluttet
- Medicover Integrated Clinical Services Sp z o o
-
Wiele, Polen, 05-135
- Aktiv, ikke rekrutterende
- Mazowiecki Szpital Onkologiczny Sp z o o
-
Wroclaw, Polen, 50 981
- Afsluttet
- 4 Wojskowy Szpital Kliniczny Z Poliklinika Samodzielny Publiczny Zaklad Opieki Zdrowotnej We Wroclawiu
-
Wroclaw, Polen, 53-413
- Aktiv, ikke rekrutterende
- Dolnoslaskie Centrum Onkologii Pulmonologii i Hematologii
-
-
-
-
-
Alzira, Spanien, 46600
- Rekruttering
- Hosp. Univ. de La Ribera
-
Barcelona, Spanien, 08025
- Rekruttering
- Fund. Puigvert
-
Barcelona, Spanien, 08036
- Rekruttering
- Hosp Clinic de Barcelona
-
Barcelona, Spanien, 08035
- Afsluttet
- Hosp Univ Vall D Hebron
-
Cadiz, Spanien, 11009
- Rekruttering
- Hosp. Puerta Del Mar
-
Castillón, Spanien, 12004
- Rekruttering
- Hosp. Gral. Univ. de Castellon
-
Jerez de la Frontera, Spanien, 11407
- Rekruttering
- Hosp. de Jerez de La Frontera
-
La Coruña (A Coruña), Spanien, 15006
- Rekruttering
- Hosp Univ A Coruna
-
Madrid, Spanien, 28041
- Rekruttering
- Hosp. Univ. 12 de Octubre
-
Madrid, Spanien, 28027
- Rekruttering
- Clinica Univ. de Navarra
-
Madrid, Spanien, 28007
- Afsluttet
- Hosp. Gral. Univ. Gregorio Maranon
-
Málaga, Spanien, 29010
- Rekruttering
- Hosp Virgen de La Victoria
-
Oviedo, Spanien, 33011
- Afsluttet
- Hosp. Univ. Central de Asturias
-
Sabadell, Spanien, 08208
- Rekruttering
- Hosp.Univ.Parc Tauli
-
Seville, Spanien, 41013
- Afsluttet
- Hosp. Virgen Del Rocio
-
Valencia, Spanien, 46010
- Rekruttering
- Hosp. Clinico Univ. de Valencia
-
-
-
-
-
Chuncheon, Sydkorea, 28644
- Afsluttet
- Chungbuk National University Hospital
-
Gyeongin, Sydkorea, 10408
- Rekruttering
- National Cancer Center
-
Sangam-dong, Sydkorea, 58128
- Rekruttering
- Chonnam National University Hwasun Hospital
-
Seoul, Sydkorea, 06351
- Rekruttering
- Samsung Medical Center
-
Seoul, Sydkorea, 3080
- Rekruttering
- Seoul National University Hospital
-
Seoul, Sydkorea, 06591
- Aktiv, ikke rekrutterende
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Hradec Králové, Tjekkiet, 500 05
- Afsluttet
- Fakultni nemocnice Hradec Kralove
-
Olomouc, Tjekkiet, 779 00
- Rekruttering
- Fakultni nemocnice Olomouc
-
Prague, Tjekkiet, 128 08
- Rekruttering
- Vseobecna fakultni nemocnice v Praze
-
Prague, Tjekkiet, 150 06
- Rekruttering
- Fakultni nemocnice v Motole
-
Prague, Tjekkiet, 140 59
- Rekruttering
- Fakultni Thomayerova nemocnice
-
-
-
-
-
?zmir, Tyrkiet (Türkiye), 35330
- Rekruttering
- Dokuz Eylul University Medical Faculty
-
Adana, Tyrkiet (Türkiye), 01120
- Afsluttet
- Adana Baskent Practice and Research Hospital
-
Ankara, Tyrkiet (Türkiye), 06200
- Rekruttering
- Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital
-
Ankara, Tyrkiet (Türkiye), 06100
- Afsluttet
- Ankara University Medical Faculty
-
Istanbul, Tyrkiet (Türkiye), 34722
- Rekruttering
- T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
-
Istanbul, Tyrkiet (Türkiye), 34153
- Afsluttet
- Istanbul University Cerrahpasa Medical Faculty
-
Istanbul, Tyrkiet (Türkiye), 34865
- Rekruttering
- Kartal Dr Lutfi Kirdar sehir Hastanesi
-
-
-
-
-
Berlin, Tyskland, 10117
- Aktiv, ikke rekrutterende
- Charite - Universitaetsmedizin Berlin (CCM)
-
Braunschweig, Tyskland, 38126
- Rekruttering
- Stadtisches Klinikum Braunschweig gGmbH-Klinik fur Urologie und Uroonkologie
-
Cologne, Tyskland, 50968
- Rekruttering
- Studienzentrum Bayenthal
-
Dresden, Tyskland, 01307
- Afsluttet
- Urologische Gemeinschaftspraxis
-
Frankfurt am Main, Tyskland, 60596
- Rekruttering
- Universitaetsklinikum Frankfurt
-
Hamburg, Tyskland, 22081
- Aktiv, ikke rekrutterende
- Urologikum Hamburg MVZ - Germany
-
Herne, Tyskland, 44625
- Rekruttering
- Marien hospital Herne
-
Jena, Tyskland, 07747
- Aktiv, ikke rekrutterende
- Universitatsklinikum Jena
-
München, Tyskland, 81675
- Afsluttet
- Klinikum rechts der Isar an der Technischen Universitat Munchen
-
Straubing, Tyskland, 94315
- Rekruttering
- Klinikum St. Elisabeth Straubing GmbH
-
Stuttgart, Tyskland, 70174
- Afsluttet
- Katharinenhospital Innere Medizin
-
-
-
-
-
Graz, Østrig, 8036
- Rekruttering
- Medizinische Universitaet Graz
-
Innsbruck, Østrig, 6020
- Rekruttering
- Medizinische Universitat Innsbruck
-
Leopoldsdorf (Wien), Østrig, 1090
- Rekruttering
- Medical University Vienna MUV
-
Linz, Østrig, 4020
- Rekruttering
- Ordensklinikum Linz GmbH Elisabethinen
-
Salzburg, Østrig, 5020
- Rekruttering
- Universitaetsklinikum Salzburg Landeskrankenhaus
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Main study only: Have a histologically confirmed diagnosis (within 90 days of randomization) of IR-NMIBC with at least one of the following criteria fulfilled: a. Ta low grade (LG)/ Grade 1 (G1): primary or recurrent, b. Ta LG/G2: primary or recurrent and c. Greater than or equal to (>=) 1 of the following risk factors: i. Multiple Ta LG tumors, ii. Solitary LG tumor >= 3 cm, iii. Early recurrence (less than [<] 1 year), iv. Frequent recurrence (greater than [>] 1 per year), v. Recurrence after prior adjuvant intravesical treatment (single perioperative dose of chemotherapy does not fulfill this risk factor)
- Substudy only: Have a histologically confirmed new diagnosis (within 90 days of randomization) of IR-NMIBC for whom MMC is deemed the therapy of choice according to local standard of care with at least 1 of the following criteria fulfilled: a. Ta LG/G1, b. Ta LG/G2, and >=1 of the following risk factors: i) Multiple Ta LG tumors, ii) Solitary LG tumor >=3 cm
- Have a susceptible fibroblast growth factor receptor (FGFR) mutation or fusion either by urine testing or tumor tissue testing (from TURBT tissue), as determined by central or local testing
- Participants must be willing to undergo all study procedures (e.g., multiple cystoscopies from Screening through the end of study and TURBT for assessment of recurrence/progression) and receive the assigned treatment, including intravesical chemotherapy if randomized into that arm.
- Visible papillary disease must be fully resected prior to randomization and absence of disease must be documented at Screening cystoscopy
- Can have a prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
- Have an Eastern Cooperative Oncology Group performance status of 0 to 2
Exclusion Criteria:
- Known allergies, hypersensitivity, or intolerance to any study component or its excipients, including: a. Erdafitinib excipients; b.TAR-210 drug delivery system constituent materials ; c. urinary placement catheter materials; d. MMC or chemically related drugs; e. Gemcitabine or chemically related drugs
- Presence of any bladder or urethral anatomic feature (that is, urethral stricture) that, in the opinion of the investigator, may prevent the safe insertion, indwelling use, removal of TAR-210 or passage of a urethral catheter for intravesical chemotherapy
- Polyuria with recorded 24-hour urine volumes > 4000 milliliters (mL)
- Current indwelling urinary catheters, however, intermittent catheterization is acceptable
- Had major surgery or had significant traumatic injury and/or not fully recovered within 4 weeks before first dose (TURBT is not considered major surgery)
Substudy:
- Previous diagnosis of histologically confirmed urothelial bladder carcinoma at any time prior to current qualifying diagnosis
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Main Study: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Andre navne:
|
|
Aktiv komparator: Main Study: Group B: MMC or Gemcitabine
Participants in Group B will receive intravesical mitomycin C (MMC) or gemcitabine (investigator's choice) once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
Gemcitabine will be administered intravesically. MMC will be administered intravesically. |
|
Eksperimentel: Substudy: Group A: TAR-210
Participants in Group A will have TAR-210 inserted in the bladder on Day 1 and removed after 12 weeks. One TAR-210 will be inserted every 12 weeks over a treatment period of approximately 1 year. |
TAR-210 will be administered intravesically.
Andre navne:
|
|
Aktiv komparator: Substudy: Group B: MMC
Participants in substudy Group B will receive intravesical MMC once weekly for 4 to 6 induction doses followed by a maintenance phase for a minimum of 6 months and up to 1 year. |
MMC will be administered intravesically. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Disease Free Survival (DFS)
Tidsramme: From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
DFS is measured as the time from randomization to the date of the first documented recurrence of Ta non-muscle invasive bladder cancer (NMIBC) of any grade, disease progression, or death due to any cause, whichever occurs first. |
From randomization to the date of the first documented recurrence, disease progression or death (approximately 4 years and 2 months)
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Time to next Treatment (TTNT)
Tidsramme: From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
TTNT is measured as the time from randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer. |
From randomization to the date of first documented subsequent treatment (local, systemic, surgical, or interventional) for bladder cancer (approximately 4 years and 2 months)
|
|
High Grade Recurrence-free Survival (HG RFS)
Tidsramme: From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
HG RFS is measured as the time from randomization to the date of first documented evidence of HG NMIBC or death, whichever occurs first |
From randomization to the date of first documented evidence of HG NMIBC or death (approximately 4 years and 2 months)
|
|
Progression Free Survival (PFS)
Tidsramme: From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
PFS is measured as the time from randomization to the date of first documented evidence of disease progression or death, whichever occurs first. |
From randomization to the date of first documented disease progression or death (approximately 4 years and 2 months)
|
|
Number of Diagnostic and Therapeutic Invasive Urological Interventions after Study Treatment
Tidsramme: From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
Number of diagnostic and therapeutic invasive urological interventions after study treatment, that is, endoscopic procedures (e.g., cystoscopies, transurethral resection of bladder tumors (TURBTs), ureteroscopies, urethral interventions, urethral stricture/bladder neck incision), catheterization (intravesical, suprapubic), intravesical treatments, major surgeries (e.g., radical cystectomy, simple cystectomy, urethroplasty) will be reported. |
From study treatment completion up to trial discontinuation (approximately 4 years and 2 months)
|
|
Number of Participants With Adverse Events (Including Physical Examination, Vital Signs and Laboratory Abnormalities)
Tidsramme: From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
An AE is any untoward medical occurrence in a participant participating in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product, that does not necessarily have a causal relationship with the treatment. AEs will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0. Severity of AEs has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening and Grade 5: Death. Number of participants with adverse events (including physical examination, vital signs and laboratory abnormalities) will be reported. |
From first dose up to 30 days after last dose of study treatment (approximately 4 years and 2 months)
|
|
Overall Survival (OS)
Tidsramme: From randomization to the date of death (approximately 4 years and 2 months)
|
OS is defined as the time from randomization to the date of death from any cause. |
From randomization to the date of death (approximately 4 years and 2 months)
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Scores
Tidsramme: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire for Non muscle Invasive Bladder Cancer (EORTC-QLQ-NMIBC24) Scores
Tidsramme: Baseline, Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Baseline, Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-C30 Scores
Tidsramme: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-C30 is a core 30-item questionnaire for evaluating the HRQoL of participants participating in cancer clinical studies. It incorporates 5 functional scales (physical, role, cognitive, emotional, and social functioning), 3 symptom scales (fatigue, pain, and nausea or vomiting), and a global health status or HRQoL scale. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
|
Percentage of Participants With Significant Change From Baseline in EORTC-QLQ-NMIBC24 Scores
Tidsramme: Weeks 6, 12, 24, 36, and 48
|
EORTC QLQ-NMIBC24 is a 24-item questionnaire for evaluating the HRQoL of participants with non-muscle-invasive bladder cancer. The questionnaire is designed to supplement the QLQ C30 and incorporates 6 multi-item scales and 5 single items. Ratings for each item range from 1 (not at all) to 4 (very much). Higher scores indicated greater severity. |
Weeks 6, 12, 24, 36, and 48
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Johnson & Johnson Enterprise Innovation Inc. Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Neoplasmer
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Urologiske neoplasmer
- Karcinom
- Urinblæresygdomme
- Urinblære neoplasmer
- Ikke-muskelinvasive blære-neoplasmer
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Deoxycytidin
- Cytidin
- Pyrimidin -nukleosider
- Pyrimidiner
- Gemcitabin
- erdafitinib
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 42756493BLC3004
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .